# An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy

> **NCT06270719** · — · ENROLLING_BY_INVITATION · sponsor: **Sarepta Therapeutics, Inc.** · enrollment: 500 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **GENETIC:** Delandistrogene Moxeparvovec
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT06270719
- **Lead sponsor:** Sarepta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-02-07
- **Primary completion:** 2029-12-31
- **Final completion:** 2038-12-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06270719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06270719, "An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06270719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*